-
Kospi Falls Below 5,000 as U.S. AI Regulation Fears Trigger Circuit Breaker
-
BYD Drops Rotating Screens in New Models Due to Tech Limits
-
Valsoft's TAG Software Group Enters the Content Operations Market with the Acquisition of Chalco
-
Samsung Leads Global DRAM Market as SK Hynix Gains Share
-
South Korea Proposes Fourth Delay of Cryptocurrency Gains Tax to 2029
-
Kakao Details Spinoff Plan to Monetize AI Through KakaoTalk
-
ASIC Fines Mona Museum Owner's Company for Late Financial Report
-
Business Leaders Condemn Productivity Commission Inquiry for Excluding Tax and Labor Issues
-
Business Leaders Criticize Productivity Commission Inquiry Scope
-
Sheikh Hasina Vows Return to Bangladesh Despite Death Sentence
-
SCANDIC FINANCE ने एलेक्स बोडी को समूह का उपाध्यक्ष नियुक्त किया
-
SCANDIC FINANCE แต่งตั้งอเล็กซ์ โบดี เป็นรองประธานกลุ่มบริษัท
-
SCANDIC FINANCE Grubu, Alex Bodi’yi başkan yardımcılığına atadı
-
Alex Bodi wiceprezesem grupy SCANDIC FINANCE
-
Алекс Боди е назначен за вицепрезидент на групата SCANDIC FINANCE
-
Alex Bodi a SCANDIC FINANCE vállalatcsoport új alelnöke
-
Ο Άλεξ Μπόντι νέος αντιπρόεδρος του ομίλου SCANDIC FINANCE
US approves first at-home cervical cancer screening device
The US Food and Drug Administration has approved an at-home cervical cancer screening tool as an alternative to Pap smears by a gynecologist, the company behind the device said Friday.
The "Teal Wand" -- a self-collection vaginal swab shaped like a tampon and developed by Teal Health -- will be available online for individuals aged 25 to 65 who are at average risk for cervical cancer.
Users request a kit online, have a brief visit with a telehealth provider to gauge eligibility and then the kit is prescribed. They then collect the sample and ship it to a lab for analysis.
Cervical cancer, which affects the lower part of the uterus, is diagnosed in about 0.6 percent of women. Although HPV vaccination and regular screening are highly effective at preventing the disease, more than one in four women fall behind on routine appointments.
"When we make care easier to get, we help women stay healthy, for themselves and for the people who rely on them every day," Teal Health CEO Kara Egan said in a statement.
The Teal Wand tests for high-risk strains of human papillomavirus (HPV), the primary cause of cervical cancer.
A large clinical trial found its accuracy comparable to a traditional Pap smear, which requires a speculum and is often cited as a barrier to screening due to discomfort.
Most sexually active people will contract HPV at some point, though only a small fraction develop cancer.
Teal Health did not disclose pricing but said it is in talks with insurers to ensure affordability. The product will launch first in California in June.
F.Cardoso--PC